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Abstract
Objective-(a) To develop an assay for streptokinase resistance. (b) To determine the prevalence of streptokinase resistance in patients presenting with acute myocardial infarction for the first time. (c) To determine the prevalence of streptokinase resistance in patients after exposure to streptokinase or streptococcal infection.
Design-Open, prospective.
Patients-30 healthy volunteers. 40 patients admitted to the coronary care unit at Addenbrooke's Hospital with suspected acute myocardial infarction, 12 patients 12 months after streptokinase treatment, eight patients 24 months after streptokinase treatment, and sera from 12 patients with raised antistreptolysin 0 (ASO) titres.
Methods-Three assays were used; a dilution neutralisation a,ssay, an enzyme linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) antistreptokinase antibodies, and an in vitro fibrin plate lysis assay. All measurements were performed on venous blood samples.
Results-Neutralisation and IgG antibody titres were positively correlated. Mean (SEM) antistreptokinase concentrations in the 30 controls were 87 (10) U/ml (neutralisation assay) and 28 (6 3) U/ml (ELISA) . Corresponding concentrations in patients before streptokinase were 68 (6-1) U/ml and 18 (4 5) U/ml with a mean fibrin plate assay 117 (7-1)% that of controls. Resistance to streptokinase was detectable in one patient after 72 hours and in all patients by day 10 . By day 10 concentrations were 4388 (919) U/ml, 773 (109) U/ml, and 17 (5 4)%. At both 12 and 24 months resistance was present in 75% of patients. Similarly 66% of high ASO titre sera showed resistance. The fibrin plate lysis assay detected significantly reduced streptokinase dependent fibrinolysis in vitro in the absence of raised total concentrations of antistreptokinase antibodies. Patients and methods
Conclusions

PATIENTS AND CONTROLS
Over a six week period, venous blood samples were taken before administration of streptokinase, from 40 patients admitted to the coronary care unit of Addenbrooke's Hospital for the first time with a suspected acute myocardial infarction. Further samples were taken on days three to four and on the day of discharge (days seven to 10) from 15 patients who had received 1-5 million units of intravenous streptokinase (Streptase, Hoechst). None of the patients had previously received streptokinase. Venous blood was also taken from (a) 12 patients who had received streptokinase 12 months previously, (b) eight patients who had received streptokinase 24 months previously, (c) 12 patients with raised antistreptolysin 0 titres, (d) 30 healthy normal controls with no documented history of streptococcal infection. All patients gave informed verbal consent, and the study was approved by the local ethics committee.
MEASUREMENT OF STREPTOCOCCAL ANTIBODIES
Immunoglobulin G antibodies to streptokinase were measured by an enzyme linked immunosorbent assay (ELISA) incorporating solid phase streptokinase. Neutralising antibodies were measured by a dilutional clot lysis assay.
(a) ELISA assay: 100 p1 of 1000 U/ml streptokinase (Streptase, Hoechst) was added to the wells of a microtitre plate (Nunc, Denmark). Plates were sealed, incubated overnight at room temperature, and washed three times in 0-01 mol/l phosphate buffered saline (PBS) and 0-5 ml/l Tween. One hundred p1 of plasma, diluted one in 40 with phosphate buffered saline (PBS)/0-1% bovine serum albumin, was then added to each well and incubated for two hours at room temperature. After three washes the wells were incubated with 100 p1 peroxidase-conjugated rabbit antihuman IgG (Dako) diluted 1/5000 in PBS/ Tween for two hours at room temperature.
After washing, 100 p1 substrate solution (3 mg/ ml orthophenylenediamine in 0-01 mol/l citrate phosphate buffer, with 0 01% hydrogen peroxide was added and the reaction stopped by the addition of 150 p1 sulphuric acid. Absorbance at 492 nm was read with a Titertek Multiscan plate reader. A standard curve was derived from doubling dilutions of normal plasma from 1/20, assigned 100 U/ml and patient samples were sufficiently diluted to enable a concentration of antibody to be found from the standard curve. The concentration of antibody in the patient sample was then multiplied by the appropriate dilution factor. A concentration > 2 SDs above the mean of the normal controls was defined as raised.
(b) Neutralisation assay: streptokinase neutralising activity was measured by a method similar to that previously reported.7 Streptokinase was diluted in saline to give a range of concentrations from 500 U/ml to 2000 U/ml. Twenty p1 of each dilution was added to 200 p1 plasma and a fibrin clot formed by the addition of 1 U bovine thrombin (Diagen). The highest concentration of streptokinase that failed to lyse the clot was used to calculate the streptokinase neutralising titre. Patient samples were diluted in normal plasma until clot lysis was achieved. The neutralising activity (U/ml) was calculated as:-highest concentration of streptokinase failing to lyse clot x dilution of test plasma in normal plasma/10. A concentration > 2 SDs above the mean of the normal controls was defined as raised.
FIBRIN PLATE LYSIS ASSAY
Fibrinogen (Diagen) was dissolved in imidazole buffer to a concentration of 650 mg/l. Fibrin plates were prepared by clotting 10 ml fibrinogen solution with 10 U bovine thrombin (Diagen) and 25 mM calcium chloride in petri dishes (Sterilin). Streptokinase was added to the plasma samples to achieve a concentration of 625 U/ml. This was the calculated plasma concentrations of streptokinase that would result from a dose of 1-5 million units to a 70 kg subject with a packed cell volume of 45%. Twenty five p1 of each plasma sample were placed on a fibrin plate and incubated at 37°C for 24 hours. The area of lysis was calculated as the product of two diameters at 900 to each other. The mean area of lysis of the 30 normal controls was 1394 mm2. All areas of lysis caused by patients plasma with added streptokinase were then reported as percentages of this value. A reduction in streptokinase dependent in vitro fibrinolysis >2 SDs below the mean normal activity was regarded as abnormal. ASO 
TITRES
Titres of ASO were measured by a standard sheep red cell haemolysin assay (Wellcome Diagnostics).
STATISTICAL ANALYSIS
Comparisons between study groups and the normal controls were performed with the Wilcoxon's ranking test for unpaired data (MannWhitney test). The same test was used for comparisons in the group tested on several days as the numbers tested on each day varied.
Results
The mean age of the 40 patients (28 men) admitted to the coronary care unit was 58 (range 38-71) years. All patients received 1-5 million units of streptokinase by a one hour intravenous infusion. None of the patients suffered an allergic reaction. Venous blood samples were taken from 15 patients on day 3 and on the day of discharge (days 7/8 in seven patients and days 9/10 in eight patients).
The ELISA assay and the neutralisation titre assay produced comparable results and were positively correlated (r = 0-55; p < 0-001).
Overall neither assay was correlated with the fibrin plate lysis assay. Between days 1 and 10 after streptokinase, however, a reduction (more than 2 SD below mean normal) in fibrin plate lysis was associated with antistreptokinase IgG concentrations above 155 U/ml and a neutralisation titre above 375 U/ml. The Of the eight patients studied at 24 months (mean age 53, range 43-62 years, two women), six had reduced fibrin plate lysis (range 3%-24%). Five of these six had raised IgG concentrations.
Of the 12 sera from patients with raised ASO titres, six had raised ELISA IgG concentrations and all of these, plus two with concentrations within the normal range, had reduced fibrin plate lysis values (range 9%-64%). Figure 3 shows the individual and mean fibrinolytic responses of each of the study groups.
Discussion
None of the patients admitted with acute myocardial infarction had raised concentrations of antistreptokinase antibodies or in vitro fibrinolytic resistance to streptokinase. The prevalence of antistreptokinase antibodies in patients presenting to the coronary care unit for the first time is therefore low and most should The results of our study suggest that up to 75% ofpatients treated once with streptokinase will -be resistant to further treatment with streptokinase containing.agents after two years. This suggests that the outcome from retreatment with streptokinase containing agents is likely to be unpredictable for a period beginning four to seven days after streptokinase doseage and lasting for more than two years. Other data suggest that this period may last for at least four years." To identify patients who would benefit from repeated treatment with streptokinase, antibody concentrations or preferably fibrin plate lysis, could be measured routinely at regular intervals after first treatment. Such information, however, would have to be available immediately on admission with a further infarct. The only way to ensure this would be for the patients to carry this information themselves. Unfortunately, none of the tests used in this study could be performed rapidly enough at the bedside to be used on admission. We believe that titrating the dose upwards on the basis of the results of an in vitro test is an impractical approach that will only increase the antigenic load and the risk of an adverse immunological reaction.
In conclusion, streptokinase is likely to remain a first line agent for thrombolytic treatment 
